Effect of cimetidine on survival after gastric cancer.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning

Standard

Effect of cimetidine on survival after gastric cancer. / Tønnesen, H; Knigge, U; Bülow, Steffen; Damm, P; Fischerman, K; Hesselfeldt, Peter; Hjortrup, A; Pedersen, I K; Pedersen, V M; Siemssen, O J.

I: Lancet, Bind 2, Nr. 8618, 1988, s. 990-992.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning

Harvard

Tønnesen, H, Knigge, U, Bülow, S, Damm, P, Fischerman, K, Hesselfeldt, P, Hjortrup, A, Pedersen, IK, Pedersen, VM & Siemssen, OJ 1988, 'Effect of cimetidine on survival after gastric cancer.', Lancet, bind 2, nr. 8618, s. 990-992. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2902494&query_hl=142>

APA

Tønnesen, H., Knigge, U., Bülow, S., Damm, P., Fischerman, K., Hesselfeldt, P., Hjortrup, A., Pedersen, I. K., Pedersen, V. M., & Siemssen, O. J. (1988). Effect of cimetidine on survival after gastric cancer. Lancet, 2(8618), 990-992. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2902494&query_hl=142

Vancouver

Tønnesen H, Knigge U, Bülow S, Damm P, Fischerman K, Hesselfeldt P o.a. Effect of cimetidine on survival after gastric cancer. Lancet. 1988;2(8618):990-992.

Author

Tønnesen, H ; Knigge, U ; Bülow, Steffen ; Damm, P ; Fischerman, K ; Hesselfeldt, Peter ; Hjortrup, A ; Pedersen, I K ; Pedersen, V M ; Siemssen, O J. / Effect of cimetidine on survival after gastric cancer. I: Lancet. 1988 ; Bind 2, Nr. 8618. s. 990-992.

Bibtex

@article{2e41466c80f14133b2cb771d7f38ff57,
title = "Effect of cimetidine on survival after gastric cancer.",
abstract = "The effect of cimetidine on survival was investigated in 181 patients with gastric cancer. Immediately after operation or the decision not to operate, the patients were randomised in double-blind fashion to placebo or cimetidine 400 mg twice daily for two years or until death, with review every three months. Median survival in the cimetidine group was 450 days (range 1-1826) and in the placebo group 316 days (1-1653). The relative survival rates (cimetidine/placebo) were 45%/28% at 1 year, 22%/13% at 2 years, 13%/7% at 3 years, 9%/3% at 4 years, and 2%/0% at 5 years. Survival in the cimetidine group was significantly longer than in the placebo group.",
author = "H T{\o}nnesen and U Knigge and Steffen B{\"u}low and P Damm and K Fischerman and Peter Hesselfeldt and A Hjortrup and Pedersen, {I K} and Pedersen, {V M} and Siemssen, {O J}",
year = "1988",
language = "English",
volume = "2",
pages = "990--992",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "8618",

}

RIS

TY - JOUR

T1 - Effect of cimetidine on survival after gastric cancer.

AU - Tønnesen, H

AU - Knigge, U

AU - Bülow, Steffen

AU - Damm, P

AU - Fischerman, K

AU - Hesselfeldt, Peter

AU - Hjortrup, A

AU - Pedersen, I K

AU - Pedersen, V M

AU - Siemssen, O J

PY - 1988

Y1 - 1988

N2 - The effect of cimetidine on survival was investigated in 181 patients with gastric cancer. Immediately after operation or the decision not to operate, the patients were randomised in double-blind fashion to placebo or cimetidine 400 mg twice daily for two years or until death, with review every three months. Median survival in the cimetidine group was 450 days (range 1-1826) and in the placebo group 316 days (1-1653). The relative survival rates (cimetidine/placebo) were 45%/28% at 1 year, 22%/13% at 2 years, 13%/7% at 3 years, 9%/3% at 4 years, and 2%/0% at 5 years. Survival in the cimetidine group was significantly longer than in the placebo group.

AB - The effect of cimetidine on survival was investigated in 181 patients with gastric cancer. Immediately after operation or the decision not to operate, the patients were randomised in double-blind fashion to placebo or cimetidine 400 mg twice daily for two years or until death, with review every three months. Median survival in the cimetidine group was 450 days (range 1-1826) and in the placebo group 316 days (1-1653). The relative survival rates (cimetidine/placebo) were 45%/28% at 1 year, 22%/13% at 2 years, 13%/7% at 3 years, 9%/3% at 4 years, and 2%/0% at 5 years. Survival in the cimetidine group was significantly longer than in the placebo group.

M3 - Journal article

VL - 2

SP - 990

EP - 992

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8618

ER -

ID: 34044693